DYES FOR USE IN A METHOD OF PHOTOPORATION OF THE INNER LIMITING MEMBRANE

Abstract

The invention concerns a dye for use in a method of photoporation of the inner limiting membrane (ILM) of an eye in a subject. Preferably, the method comprises: administering the dye to the vitreous chamber of the eye of the subject; and irradiating at least part of the ILM of the eye of the subject, thereby photoporating at least part of the ILM in the subject. The invention further relates to a dye and optionally a therapeutic agent for use in a method of treating a retinal disease or a choroidal disease of an eye in a subject.

Description

Claims

1. A a method of photoporation of the inner limiting membrane (ILM) of an eye in a subject, wherein the method comprises: - administering a dye to a vitreous chamber of the eye of the subject; and- irradiating at least part of the ILM of the eye of the subject, thereby photoporating at least part of the ILM in the subject.

2. (canceled)

3. A a method of treating a retinal disease or a choroidal disease of an eye in a subject, wherein the method comprises: - administering a dye to a vitreous chamber of the eye of the subject;- irradiating at least part of an inner limiting membrane (ILM) of the eye of the subject, thereby photoporating at least part of the ILM: and- administering a therapeutic agent to the vitreous chamber of the eye of the subject, thereby treating the retinal disease or the choroidal disease in the subject; or wherein the method comprises: - administering the dye and the therapeutic agent to the vitreous chamber of an eye of the subject; and- irradiating at least part of the ILM of the eye of the subject, thereby photoporating at least part of the ILM and treating the retinal disease or the choroidal disease in the subject.

4. (canceled)

5. The method according to claim 3, wherein the dye is a vital dye.

6. The method according to claim 3, wherein the dye is a vital dye selected from the group consisting of: Indocyanine Green (ICG), Trypan Blue (TB), Brilliant Blue (BB), Janus green B (JG), Gentian violet (GV), Bromophenol Blue (BPB), Patent blue (PB), Light Green (LG), Fast Green (FG), Infracyanine Green (IfCG), Methylene blue (MB), Toluidine blue (ToB), Fluorescein Sodium (FS), Rose Bengal (RB), and Rhodamine 6G (R6G); preferably wherein the dye is ICG.

7. The method according to claim 3, wherein the dye is administered at a concentration of about 0.001 mg/ml to about 0.5 mg/ml.

8. The method according to claim 3, wherein the dye is a free dye, an aggregate of the dye, or a crystal of the dye; wherein the dye is conjugated to a further agent; wherein the dye is comprised in a nanoparticle; and/or wherein the dye and the therapeutic agent are comprised in a nanoparticle.

9. The method according to claim 3, wherein the therapeutic agent is a retinal disease drug or a choroidal disease drug.

10. The method according to claim 3, wherein the therapeutic agent is selected from the group consisting of a stem cell, a protein, a polypeptide, a peptide, an antibody, an antibody fragment, an antibody-like protein scaffold, an aptamer, a photoaptamer, a spiegelmer, a peptidomimetic, a gene-editing system, a nucleic acid, and combinations thereof.

11. The method according to claim 3, wherein the therapeutic agent is comprised in a viral vector or in a nanoparticle.

12. The method according to claim 3, 3 wherein the dye and/or the therapeutic agent is administered to the vitreous body by intravitreal injection.

13. The method according to claim 3, wherein the dye and/or the therapeutic agent is administered by injection into the vitreous chamber after removal of the vitreous body.

14. The method according to claim 3, wherein the at least part of the ILM is irradiated with electromagnetic radiation; preferably wherein the at least part of the ILM is irradiated with laser radiation; more preferably wherein the at least part of the ILM is irradiated with pulsed-laser radiation.

15. The method according to claim 3, wherein the retinal disease or the choroidal disease is selected from the group consisting of inherited retinal dystrophies, acquired diseases of the retina or choroid, inflammatory diseases of the retina or choroid, vascular diseases of the retina or choroid, neoplastic diseases of the retina or choroid, ocular traumas, retinal tractional defects, and toxic retinopathy.

16. The method according to claim 3, wherein the retinal disease is selected from the group consisting of macular degeneration, diabetic retinopathy, retinitis pigmentosa, glaucoma, retinoblastoma, and inherited retinal dystrophies.

17. The method according to claim 3, wherein the choroidal disease is selected from the group consisting of central serous chorioretinopathy, polypoidal choroidal vasculopathy, choroidal melanoma, choroidal neovascularization, choroideremia, and choroidal dystrophies.

18. (canceled)

19. The method according to claim 1, wherein one or more of: - the dye is a vital dye;- the dye is a vital dye selected from the group consisting of: Indocyanine Green (ICG), Trypan Blue (TB), Brilliant Blue (BB), Janus green B (JG), Gentian violet (GV), Bromophenol Blue (BPB), Patent blue (PB), Light Green (LG), Fast Green (FG), Infracyanine Green (IfCG), Methylene blue (MB), Toluidine blue (ToB), Fluorescein Sodium (FS), Rose Bengal (RB), and Rhodamine 6G (R6G); preferably wherein the dye is ICG;- the dye is administered at a concentration of about 0.001 mg/ml to about 0.5 mg/ml;- the dye is a free dye, an aggregate of the dye, or a crystal of the dye;- the dye is conjugated to a further agent; the dye is comprised in a nanoparticle; and/or the dye and the therapeutic agent are comprised in a nanoparticle;- the therapeutic agent is a retinal disease drug or a choroidal disease drug;- the therapeutic agent is selected from the group consisting of a stem cell, a protein, a polypeptide, a peptide, an antibody, an antibody fragment, an antibody-like protein scaffold, an aptamer, a photoaptamer, a spiegelmer, a peptidomimetic, a gene-editing system, a nucleic acid, and combinations thereof;- the therapeutic agent is comprised in a viral vector or in a nanoparticle;- the dye and/or the therapeutic agent is administered to the vitreous body by intravitreal injection;- the dye and/or the therapeutic agent is administered by injection into the vitreous chamber after removal of the vitreous body; and/or- the at least part of the ILM is irradiated with electromagnetic radiation; preferably wherein the at least part of the ILM is irradiated with laser radiation; more preferably wherein the at least part of the ILM is irradiated with pulsed-laser radiation.

20-21. (canceled)

22. A method for delivering a therapeutic agent to the retina or the choroid of an eye in a subject, the method comprising: - administering a dye to the vitreous chamber of the eye of the subject;- irradiating at least part of an inner limiting membrane (ILM)the ILM of the eye of the subject, thereby photoporating at least part of the ILM; and- administering the therapeutic agent to the vitreous chamber of the eye of the subject; or the method comprising: - administering the dye and the therapeutic agent to the vitreous chamber of an eye of the subject; and- irradiating at least part of the ILM of the eye of the subject, thereby photoporating at least part of the ILM.

23. The method according to claims 22, wherein one or more of: - the dye is a vital dye;- the dye is a vital dye selected from the group consisting of: Indocyanine Green (ICG), Trypan Blue (TB), Brilliant Blue (BB), Janus green B (JG), Gentian violet (GV), Bromophenol Blue (BPB), Patent blue (PB), Light Green (LG), Fast Green (FG), Infracyanine Green (IfCG), Methylene blue (MB), Toluidine blue (ToB), Fluorescein Sodium (FS), Rose Bengal (RB), and Rhodamine 6G (R6G); preferably wherein the dye is ICG;- the dye is administered at a concentration of about 0.001 mg/ml to about 0.5 mg/ml;- the dye is a free dye, an aggregate of the dye, or a crystal of the dye;- the dye is conjugated to a further agent; the dye is comprised in a nanoparticle; and/or the dye and the therapeutic agent are comprised in a nanoparticle;- the therapeutic agent is a retinal disease drug or a choroidal disease drug;- the therapeutic agent is selected from the group consisting of a stem cell, a protein, a polypeptide, a peptide, an antibody, an antibody fragment, an antibody-like protein scaffold, an aptamer, a photoaptamer, a spiegelmer, a peptidomimetic, a gene-editing system, a nucleic acid, and combinations thereof;- the therapeutic agent is comprised in a viral vector or in a nanoparticle;- the dye and/or the therapeutic agent is administered to the vitreous body by intravitreal injection;- the dye and/or the therapeutic agent is administered by injection into the vitreous chamber after removal of the vitreous body;- the at least part of the ILM is irradiated with electromagnetic radiation; preferably wherein the at least part of the ILM is irradiated with laser radiation; more preferably wherein the at least part of the ILM is irradiated with pulsed-laser radiation;- the retinal disease or the choroidal disease is selected from the group consisting of inherited retinal dystrophies, acquired diseases of the retina or choroid, inflammatory diseases of the retina or choroid, vascular diseases of the retina or choroid, neoplastic diseases of the retina or choroid, ocular traumas, retinal tractional defects; and toxic retinopathy;- the retinal disease is selected from the group consisting of macular degeneration, diabetic retinopathy, retinitis pigmentosa, glaucoma, retinoblastoma, and inherited retinal dystrophies; and/or- the choroidal disease is selected from the group consisting of central serous chorioretinopathy, polypoidal choroidal vasculopathy, choroidal melanoma, choroidal neovascularization, choroideremia, and choroidal dystrophies.